Advertisement

In-Press Preview Research ArticleTherapeutics Free access | 10.1172/JCI96148

TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer

Ke Gong, Gao Guo, David E. Gerber, Boning Gao, Michael Peyton, Chun Huang, John D. Minna, Kimmo J. Hatanpaa, Kemp Kernstine, Ling Cai, Yang Xie, Hong Zhu, Farjana Fattah, Shanrong Zhang, Masaya Takahashi, Bipasha Mukherjee, Sandeep Burma, Jonathan Dowell, Kathryn Dao, Vassiliki A. Papadimitrakopoulou, Victor Olivas, Trever G. Bivona, Dawen Zhao, and Amyn A. Habib

Find articles by Gong, K. in: JCI | PubMed | Google Scholar

Find articles by Guo, G. in: JCI | PubMed | Google Scholar

Find articles by E. Gerber, D. in: JCI | PubMed | Google Scholar

Find articles by Gao, B. in: JCI | PubMed | Google Scholar

Find articles by Peyton, M. in: JCI | PubMed | Google Scholar

Find articles by Huang, C. in: JCI | PubMed | Google Scholar

Find articles by D. Minna, J. in: JCI | PubMed | Google Scholar

Find articles by J. Hatanpaa, K. in: JCI | PubMed | Google Scholar

Find articles by Kernstine, K. in: JCI | PubMed | Google Scholar

Find articles by Cai, L. in: JCI | PubMed | Google Scholar

Find articles by Xie, Y. in: JCI | PubMed | Google Scholar

Find articles by Zhu, H. in: JCI | PubMed | Google Scholar

Find articles by Fattah, F. in: JCI | PubMed | Google Scholar

Find articles by Zhang, S. in: JCI | PubMed | Google Scholar

Find articles by Takahashi, M. in: JCI | PubMed | Google Scholar

Find articles by Mukherjee, B. in: JCI | PubMed | Google Scholar

Find articles by Burma, S. in: JCI | PubMed | Google Scholar

Find articles by Dowell, J. in: JCI | PubMed | Google Scholar

Find articles by Dao, K. in: JCI | PubMed | Google Scholar

Find articles by A. Papadimitrakopoulou, V. in: JCI | PubMed | Google Scholar

Find articles by Olivas, V. in: JCI | PubMed | Google Scholar

Find articles by G. Bivona, T. in: JCI | PubMed | Google Scholar

Find articles by Zhao, D. in: JCI | PubMed | Google Scholar

Find articles by A. Habib, A. in: JCI | PubMed | Google Scholar

First published April 3, 2018 - More info

J Clin Invest. https://doi.org/10.1172/JCI96148.
Copyright © 2018, American Society for Clinical Investigation

First published April 3, 2018
Abstract

Although aberrant Epidermal Growth Factor Receptor (EGFR) signaling is widespread in cancer, EGFR inhibition is effective only in a subset of NSCLC (non-small cell lung cancer) with EGFR activating mutations. A majority of NSCLCs express EGFR wild type (EGFRwt) and do not respond to EGFR inhibition. Tumor necrosis factor (TNF) is a major mediator of inflammation-induced cancer. We find that a rapid increase in TNF level is a universal adaptive response to EGFR inhibition in NSCLC regardless of EGFR status. EGFR signaling actively suppresses TNF mRNA levels by inducing expression of miR-21 resulting in decreased TNF mRNA stability. Conversely, EGFR inhibition results in loss of miR-21 and increased TNF mRNA stability. In addition, TNF-induced NF-kB activation leads to increased TNF transcription in a feedforward loop. Inhibition of TNF signaling renders EGFRwt expressing NSCLC cell lines and an EGFRwt Patient-Derived Xenograft (PDX) model highly sensitive to EGFR inhibition. In EGFR mutant oncogene-addicted cells, blocking TNF enhances the effectiveness of EGFR inhibition. EGFR plus TNF inhibition is also effective in NSCLC with acquired resistance to EGFR inhibition. We suggest concomitant EGFR and TNF inhibition as a new treatment approach that could be beneficial for a majority of lung cancer patients.

Supplemental material

View Supplementary Figures

View Supplementary Table

View Supplementary Methods

Version history
  • Version 1 (April 3, 2018): In-Press Preview
Advertisement
Advertisement